These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 15101473

  • 1. ACE inhibitors vs. angiotensin II receptor blockers in acute myocardial infarction and heart failure.
    Gold JA, Rahko PS.
    WMJ; 2004; 103(1):71-2. PubMed ID: 15101473
    [No Abstract] [Full Text] [Related]

  • 2. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 3. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?].
    Landmark K, Reikvam A.
    Tidsskr Nor Laegeforen; 2005 Jan 06; 125(1):38-40. PubMed ID: 15643463
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 06; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 5. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Oct 06; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 6. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 06; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 7. [The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure].
    Kárpáti P.
    Orv Hetil; 2005 May 01; 146(18):827-31. PubMed ID: 15926627
    [Abstract] [Full Text] [Related]

  • 8. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul 01; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 9. Ongoing Clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction.
    McMurray J, Berry C.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 01; 1(2):131-6. PubMed ID: 11967803
    [No Abstract] [Full Text] [Related]

  • 10. ACE inhibitors or AT(1) receptor blockers in heart failure?
    Rydén L.
    Eur Heart J; 1999 Sep 01; 20(18):1287-9. PubMed ID: 10462459
    [No Abstract] [Full Text] [Related]

  • 11. A hard look at angiotensin receptor blockers in heart failure.
    Gring CN, Francis GS.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1841-6. PubMed ID: 15519017
    [Abstract] [Full Text] [Related]

  • 12. [Is there an indication for the association of betablockers and angiotensin II receptor antagonists in cardiac failure?].
    Jondeau G, Milleron O, Morisson-Castagnet JF.
    Arch Mal Coeur Vaiss; 2004 Jun 02; 97(6):641-6. PubMed ID: 15283038
    [Abstract] [Full Text] [Related]

  • 13. A pragmatic approach to the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction.
    Vantrimpont P, Rouleau JL.
    Can J Cardiol; 1996 Oct 02; 12(10):924-9. PubMed ID: 9191482
    [Abstract] [Full Text] [Related]

  • 14. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 15. Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients.
    Baer JT, Sauer WH, Berlin JA, Kimmel SE.
    Am J Cardiol; 2004 Aug 15; 94(4):479-81. PubMed ID: 15325933
    [Abstract] [Full Text] [Related]

  • 16. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 15; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 17. Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Singh RK, Barker S.
    Curr Opin Investig Drugs; 2005 Mar 15; 6(3):269-74. PubMed ID: 15816503
    [Abstract] [Full Text] [Related]

  • 18. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 19. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS, Morillo CA, Connolly SJ.
    Curr Opin Cardiol; 2005 Jan 16; 20(1):31-7. PubMed ID: 15596957
    [Abstract] [Full Text] [Related]

  • 20. Are angiotensin-receptor blockers (ARBs) equivalent to or better than angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart failure?
    Reigle J.
    Crit Care Nurse; 2004 Dec 16; 24(6):67-9. PubMed ID: 15646090
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.